RayzeBio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.rayzebio.com
Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06726161
- Locations
- 🇺🇸
Research Facility, Grand Rapids, Michigan, United States
Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT06590857
- Locations
- 🇺🇸
Research Facility, Indianapolis, Indiana, United States
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05595460
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT05477576
- Locations
- 🇪🇸
Research Facility, Zaragoza, Spain
© Copyright 2024. All Rights Reserved by MedPath